{"entity":{"id":"nct06549465","kind":"trial","name":"Study Evaluating Dosimetry, Randomized Dose Optimization, Dose Escalation and Efficacy of Ac-225 Rosopatamab Tetraxetan in Participants With PSMA PET-Positive Castration-Resistant Prostate Cancer (CRPC)","aka":[],"tldr":"A phase 2 trial of the actinium-225 antibody rosopatamab tetraxetan (with an indium-111 version for dosimetry) in prostate cancer, run by Convergent Therapeutics, now recruiting.","summary":"Study Evaluating Dosimetry, Randomized Dose Optimization, Dose Escalation and Efficacy of Ac-225 Rosopatamab Tetraxetan in Participants With PSMA PET-Positive Castration-Resistant Prostate Cancer (CRPC) is a phase 2 interventional study registered as NCT06549465 by Convergent Therapeutics, with 93 participants planned, started 2024-08-06 and due to reach its primary completion in August 2027 (estimated; moved from 20 April 2027 in the registry update of 2 October 2026). Interventions recorded: In-111 rosopatamab tetraxetan, 45 kBq/kg Ac-225 rosopatamab tetraxetan, 45 kBq/kg or equivalent fixed dose activity Ac-225 rosopatamab tetraxetan, 60 kBq/kg Ac-225 rosopatamab tetraxetan, Single dose 22 kBq/kg or equivalent fixed dose activity Ac-225 rosopatamab tetraxetan and Single dose 34 kBq/kg or equivalent fixed dose activity Ac-225 rosopatamab tetraxetan.","status":"recruiting","asOf":"2026-10-11","links":[{"label":"ClinicalTrials.gov NCT06549465","url":"https://clinicaltrials.gov/study/NCT06549465"}],"tags":["pipeline","ctgov-ingest"],"related":["in-111","ac-225"],"indications":["prostate"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["convergent-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06549465","phase":"2","setting":"A Phase 2, Open-label Study Evaluating Dosimetry, Randomized Dose Optimization, Dose Escalation and Efficacy of Ac-225 Rosopatamab Tetraxetan in Participants With PSMA PET-Positive Castration-Resistant Prostate Cancer","sponsor":"Convergent Therapeutics","enrolled":93,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06549465/","neighbours":{"isotope":[{"id":"ac-225","kind":"isotope","name":"Actinium-225","route":"/isotopes/ac-225/"},{"id":"in-111","kind":"isotope","name":"Indium-111","route":"/isotopes/in-111/"}],"indication":[{"id":"prostate","kind":"indication","name":"Prostate cancer","route":"/indications/prostate/"}],"company":[{"id":"convergent-therapeutics","kind":"company","name":"Convergent Therapeutics","route":"/companies/convergent-therapeutics/"}]}}